Related Experiment Video
Updated: Apr 14, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice]
Agustín Albillos1, José Luis Calleja2, Esther Molina3
1Servicio de Gastroenterología, Hospital Universitario Ramón y Cajal, CIBERehd, Universidad de Alcalá, Madrid, España.
Abstract:
The first-line option in the treatment of patients with advanced fibrosis and cirrhosis due to genotype 1 hepatitis C virus is currently triple therapy with boceprevir/telaprevir and pegylated interferon-ribavirin. However, certain limitations could constitute a barrier to starting treatment or achieving sustained viral response in these patients. These limitations include the patient's or physician's perception of treatment effectiveness in routine clinical practice-which can weight against the decision to start treatment-, the advanced stage of the disease with portal hypertension and comorbidity, treatment interruption due to poor adherence, and adverse effects, mainly anemia. In addition, it is now possible to identify patients who could benefit from a shorter therapeutic regimen with a similar cure rate. This review discusses these issues and their possible effect on the use of triple therapy.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Venous Thrombosis III: Interprofessional Care
Chronic Pancreatitis II: Collaborative Care
Assessment:
Heart Failure VI: Adjunct Therapies
Nephrotic Syndrome III : Nursing Management

